Condition
Preventable Disease, Vaccine
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 2 (1)
Trial Status
Completed2
Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06489964Not ApplicableRecruitingPrimary
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
NCT05178134Phase 2Completed
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
NCT04970836Not ApplicableRecruiting
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
NCT04567342Not ApplicableCompletedPrimary
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination
NCT06357650Not Yet Recruiting
Collaborative Open Research Initiative Study (CORIS-1)
Showing all 5 trials